By continuing to use the site you agree to our Privacy & Cookies policy

NICE puts onus on pharma giant after rejecting 'costly' breast cancer drug

The National Institute for Health and Care Excellence has taken the unprecedented step of expressing its “disappointment” with a multinational drug giant in a row over a new breast cancer drug and government’s pricing deal with the pharmaceutical industry.

Get unlimited access

As a subscriber you will benefit from:

  • Full online and mobile access to news and opinion stories
  • Customised email alerts straight to your inbox (over 30 alerts available)
  • 4,500 practice articles in our archive 
  • Over £500 worth of CPD learning units